Key Advances in Acute Myeloid Leukemia From ASH 2022

Harry P. Erba, MD, PhD


January 30, 2023

Dr Harry Erba, from Duke University, Durham, North Carolina, discusses his picks of the key advances in acute myeloid leukemia (AML) presented at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition.

Dr Erba begins with three studies examining fundamental questions about the optimal induction regimen for newly diagnosed AML.

The first looked at whether 60 mg/m2 of daunorubicin (DO) is sufficient for induction, and whether good responders can omit a second induction cycle. In both cases, less is more.

Next, the UK NCRI AML19 trial showed that fludarabine, cytarabine, idarubicin, and G-CSF (FLAG-Ida) plus gemtuzumab ozogamicin (GO) improved survival outcomes over GO plus DO, especially in NPM1- and FLT3-mutated subgroups.

The third induction study examined by Dr Erba is an exploratory analysis suggesting that liposomal daunorubicin and cytarabine offered a survival benefit over FLAG-Ida in young high-risk patients.

Dr Erba then turns to an update of the VIALE-A trial, which showed continued benefit of the combination venetoclax plus azacitidine versus azacitidine alone in untreated AML patients. The recent data showed an overall survival of 14.7 months, and 10% to 20% of patients were still alive at 5 years.

He closes by reporting on two studies of novel menin inhibitors: one examining revumenib, the second using ziftomenib. Both indicated that further investigation of these agents is warranted.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.